Sitagliptin/pioglitazone

Drug Profile

Sitagliptin/pioglitazone

Alternative Names: Janacti; MK-0431C; Pioglitazine/sitagliptin

Latest Information Update: 01 Sep 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck & Co
  • Class Antihyperglycaemics; Pyrazines; Thiazolidinediones; Triazoles
  • Mechanism of Action CD26 antigen inhibitors; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Submission Withdrawal Type 2 diabetes mellitus

Most Recent Events

  • 28 Aug 2014 Takeda completes a 10-year epidemiology study as part of its post-marketing commitment to submit data to the regulatory authorities in the US, EU and Japan for pioglitazone and piogliazone-containing medicines
  • 14 Nov 2011 Regulatory submission withdrawn for Type-2 diabetes mellitus in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top